Skip to main content
. 2013 Sep 19;145(1):108–112. doi: 10.1378/chest.13-1071

Figure 1.

Figure 1.

Time-dependent effect of sirolimus therapy on detection of circulating cells with TSC2 LOH in blood and urine specimens from patients with lymphangioleiomyomatosis (LAM). A, Significant decrease in detection rate of LAM cells with TSC2 LOH in blood and urine from 12 patients receiving sirolimus therapy with a mean follow-up of −0.6 ± 0.3 to 2.2 ± 0.4 y. B, Detection of LAM cells with TSC2 LOH decreased more rapidly in urine samples than in blood samples within 1 y of sirolimus therapy. LOH = loss of heterozygosity.